Cogent Biosciences (COGT)
Develops bezuclastinib and other mutation-targeted therapies for mast-cell disease and cancer.
$31.39
vs last close−1.25 (−3.82%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 108.23% | 187.81M shares | |
|---|---|---|---|
| 336 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 6.01% | 10.43M shares | |
| 7 holders · as of May 21, 2026 | |||
| Adds to | 114.24% | ||
173.52M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 114.24%; nothing is left for Other.
13F, as of Jun 30, 2026
336 holders · 187.81M shares · 68 new positions · 205 increased · 87 reduced · 46 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| FMR LLC | 25.68M | 14.80% | +2.56M | Aug 13, 2026 |
| BlackRock, Inc. | 17.35M | 10.00% | +1.31M | Aug 7, 2026 |
| Vanguard Portfolio Management LLC | 8.07M | 4.65% | +739.1K | Aug 13, 2026 |
| Vanguard Capital Management LLC | 7.41M | 4.27% | +517.4K | Aug 13, 2026 |
| State Street Corp | 6.96M | 4.01% | +1.30M | Aug 7, 2026 |
| Jupiter Topco LLC | 6.62M | 3.82% | +6.62Mnew | Aug 14, 2026 |
| Fairmount Funds Management LLC | 5.50M | 3.17% | 0 | Aug 14, 2026 |
| Deerfield Management Company, L.P. (Series C) | 5.01M | 2.88% | −4.04M | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| FMR LLC | 15.00% | 16.57M | 13G | Feb 12, 2025 |
| Fairmount Funds Management LLCincl. Fairmount Healthcare Fund II GP LLC | 8.60% | 15.36M | 13D | Mar 31, 2026 |
| BlackRock, Inc. | 6.50% | 11.37M | 13G | Jan 21, 2026 |
| Deerfield Mgmt, L.P. | 5.29% | 9.04M | 13G | May 14, 2026 |
| Vanguard Capital Management | 5.08% | 8.69M | 13G | Jul 31, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 27, 2026 | Arlene Morrisdirector | Sale · 2 lots | 45,510 | $37.12 | 0 |
| Mar 31, 2026 | Fairmount Funds Management LLCdirector | Sale | 7,000,000 | $34.66 | 5,503,418 |
| Jan 22, 2026 | Fairmount Funds Management LLCdirector | Sale | 3,500,000 | $36.40 | 5,503,418 |
| Dec 26, 2025 | John Edward Robinsonofficer: Chief Scientific Officer | Sale | 90,000 | $38.74 | 140,002 |
| Dec 26, 2025 | Jessica Sachsofficer: Chief Medical Officer | Sale | 82,642 | $38.70 | 133,938 |
| Dec 26, 2025 | John L. Greenofficer: Chief Financial Officer | Sale | 77,000 | $38.68 | 131,834 |
| Dec 26, 2025 | Evan Kearnsofficer: Chief Legal Officer | Sale | 65,000 | $38.70 | 109,398 |
House and Senate disclosures
Not reported.